Literature DB >> 9410915

Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus.

B Ludvik1, J J Nolan, A Roberts, J Baloga, M Joyce, J M Bell, J M Olefsky.   

Abstract

The role of splanchnic glucose uptake (SGU) after oral glucose administration as a potential factor contributing to postprandial hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) has not been established conclusively. Therefore, we investigated SGU in six patients with NIDDM and six weight-matched control subjects by means of the hepatic vein catheterization (HVC) technique. In a second part, we examined the applicability of the recently developed OG-CLAMP technique in NIDDM by comparing SGU and first-pass SGU during HVC with SGU during the OG-CLAMP experiment. The OG-CLAMP method combines a euglycemic, hyperinsulinemic clamp and an oral glucose tolerance test (75 g) during steady state glucose infusion (GINF). During HVC, SGU equals the splanchnic fractional extraction times the total (oral and arterial) glucose load presented to the liver. For OG-CLAMP, SGU was calculated as first-pass SGU by subtracting the integrated decrease in GINF over 180 min from 75 g. Cumulative splanchnic glucose output after oral glucose correlated significantly between both methods and was increased significantly in NIDDM patients (73.1+/-5.1 g for HVC, 76.5+/-5.5 for OG-CLAMP) compared with nondiabetic patients (46.7+/-4.4 g for HVC, 57.5+/-1.9 for OG-CLAMP). Thus, in NIDDM patients, SGU (7.4+/-2.1 vs. 37.8+/-5.9% in nondiabetic patients, P < 0.001) and first-pass SGU (4.7+/-1.7 vs. 26.5+/-5.1% in nondiabetic patients, P < 0.01) were decreased significantly during HVC, as was SGU during OG-CLAMP (3.9+/-1.7 vs. 23.4+/-2.5% in nondiabetic patients, P < 0.0001). SGU measured during OG-CLAMP correlated significantly with SGU (r = 0.87, P < 0.05 for NIDDM patients; r = 0.94, P < 0.01 for nondiabetic patients) and first-pass SGU (r = 0.87, P < 0.05 for NIDDM patients; r = 0.84, P < 0.05 for nondiabetic patients) during HVC. In conclusion, (a) SGU after oral glucose administration is decreased in NIDDM as measured by both methods, and (b) SGU during the OG-CLAMP is well-correlated to SGU and first-pass SGU during HVC in NIDDM. The decrease in SGU in NIDDM might contribute to postprandial hyperglycemia in diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9410915      PMCID: PMC508433          DOI: 10.1172/JCI119775

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Glucagon antibodies and an immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; L L MADISON
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

2.  Absorption of glucose and methionine from the human intestine; the influence of the glucose concentration in the blood and in the intestinal lumen.

Authors:  A J CUMMINS
Journal:  J Clin Invest       Date:  1952-10       Impact factor: 14.808

Review 3.  Assessment of insulin sensitivity in vivo.

Authors:  R N Bergman; D T Finegood; M Ader
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

4.  Influence of maturity-onset diabetes on splanchnic glucose balance after oral glucose ingestion.

Authors:  P Felig; J Wahren; R Hendler
Journal:  Diabetes       Date:  1978-02       Impact factor: 9.461

5.  The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man.

Authors:  E Ferrannini; J Wahren; P Felig; R A DeFronzo
Journal:  Metabolism       Date:  1980-01       Impact factor: 8.694

6.  Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients.

Authors:  P C Butler; R A Rizza
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

7.  Contribution of splanchnic and peripheral vascular tissues to the disposal of angiotensin-II and to regional conversion rates of angiotensin-I: a pilot study in humans.

Authors:  S Gasic; C H Kleinbloesem; G Heinz; W Waldhäusl
Journal:  J Cardiovasc Pharmacol       Date:  1991-04       Impact factor: 3.105

8.  In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.

Authors:  R Prager; P Wallace; J M Olefsky
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

9.  Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.

Authors:  R G Firth; P M Bell; H M Marsh; I Hansen; R A Rizza
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

10.  The disposal of an oral glucose load in patients with non-insulin-dependent diabetes.

Authors:  E Ferrannini; D C Simonson; L D Katz; G Reichard; S Bevilacqua; E J Barrett; M Olsson; R A DeFronzo
Journal:  Metabolism       Date:  1988-01       Impact factor: 8.694

View more
  18 in total

1.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

2.  Computational assessment of insulin secretion and insulin sensitivity from 2-h oral glucose tolerance tests for clinical use for type 2 diabetes.

Authors:  Masayoshi Seike; Takeo Saitou; Yasuhiro Kouchi; Takeshi Ohara; Munehide Matsuhisa; Kazuhiko Sakaguchi; Koji Tomita; Keisuke Kosugi; Atsunori Kashiwagi; Masato Kasuga; Masaru Tomita; Yasuhiro Naito; Hiromu Nakajima
Journal:  J Physiol Sci       Date:  2011-05-19       Impact factor: 2.781

3.  Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus.

Authors:  M Mevorach; A Giacca; Y Aharon; M Hawkins; H Shamoon; L Rossetti
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

4.  Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal.

Authors:  Dan Zheng; Viorica Ionut; Vahe Mooradian; Darko Stefanovski; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

5.  Portal infusion of escitalopram enhances hepatic glucose disposal in conscious dogs.

Authors:  Zhibo An; Mary C Moore; Jason J Winnick; Ben Farmer; Doss W Neal; Margaret Lautz; Marta Smith; Tiffany Rodewald; Alan D Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

6.  A physiological increase in the hepatic glycogen level does not affect the response of net hepatic glucose uptake to insulin.

Authors:  Jason J Winnick; Zhibo An; Mary Courtney Moore; Christopher J Ramnanan; Ben Farmer; Masakazu Shiota; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-26       Impact factor: 4.310

7.  Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.

Authors:  Dan Zheng; Viorica Ionut; Vahe Mooradian; Darko Stefanovski; Richard N Bergman
Journal:  Diabetes       Date:  2008-11-14       Impact factor: 9.461

8.  Portal vein glucose entry triggers a coordinated cellular response that potentiates hepatic glucose uptake and storage in normal but not high-fat/high-fructose-fed dogs.

Authors:  Katie C Coate; Guillaume Kraft; Jose M Irimia; Marta S Smith; Ben Farmer; Doss W Neal; Peter J Roach; Masakazu Shiota; Alan D Cherrington
Journal:  Diabetes       Date:  2012-10-01       Impact factor: 9.461

9.  Hepatic glycogen supercompensation activates AMP-activated protein kinase, impairs insulin signaling, and reduces glycogen deposition in the liver.

Authors:  Jason J Winnick; Zhibo An; Christopher J Ramnanan; Marta Smith; Jose M Irimia; Doss W Neal; Mary Courtney Moore; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

10.  Liver glycogen loading dampens glycogen synthesis seen in response to either hyperinsulinemia or intraportal glucose infusion.

Authors:  Jason J Winnick; Zhibo An; Guillaume Kraft; Christopher J Ramnanan; Jose M Irimia; Marta Smith; Margaret Lautz; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.